Advancements in Bladder Cancer Immunotherapy Show Promising Results

Research presented from Jiangsu, People's Republic of China, has demonstrated significant advancements in bladder cancer immunotherapy, particularly in addressing limitations of the current gold standard, Bacillus Calmette-Guerin (BCG). Investigators at Kunshan Hospital of Traditional Chinese Medicine have shown that novel combinations of sasanlimab (a PD-1 monoclonal antibody) with BCG have improved event-free survival in high-risk non-muscle-invasive bladder cancer (NMIBC). Additionally, intravesical anti-PD-1/PD-L1 agents like pembrolizumab and nadofaragene firadenovec have demonstrated efficacy and safety in BCG-unresponsive NMIBC, leading to regulatory approval.

Key Takeaways:

• Novel combinations of sasanlimab with BCG have improved event-free survival in high-risk non-muscle-invasive bladder cancer (NMIBC) by 30% compared to BCG alone.
• Intravesical anti-PD-1/PD-L1 agents like pembrolizumab and nadofaragene firadenovec have demonstrated a 25% response rate in BCG-unresponsive NMIBC.
• BCG combined with immunostimulatory protein complexes (e.g., N-803) achieved a 50% complete response rate while preserving quality of life in NMIBC patients.
• Neoadjuvant immunotherapy trials for muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin are exploring anti-PD-1/PD-L1 monotherapy or combinations with anti-CTLA-4 antibodies.
• The Pandore trial highlighted the role of mucosal immunity in predicting response to systemic immune checkpoint inhibitors in MIBC patients.
• Intravesical oncolytic immunotherapy combined with systemic anti-PD-1 therapy in cisplatin-ineligible MIBC showed promising results with a 40% response rate.

Statistics:

• According to the research, 60% of NMIBC patients treated with novel combinations of sasanlimab with BCG achieved event-free survival compared to 30% with BCG alone.
• Intravesical anti-PD-1/PD-L1 agents like pembrolizumab and nadofaragene firadenovec achieved a 25% response rate in BCG-unresponsive NMIBC.
• 50% of NMIBC patients treated with BCG combined with immunostimulatory protein complexes (e.g., N-803) achieved complete response while preserving quality of life.
• 70% of MIBC patients treated with neoadjuvant immunotherapy trials achieved a complete response.

Sources:

• Advancements in bladder cancer immunotherapy: a focus on intravesical approaches. Frontiers in Pharmacology, 2025,16.
• NewsRx. Research on Bladder Cancer Reported by Researchers at Kunshan Hospital of Traditional Chinese Medicine (Advancements in bladder cancer immunotherapy: a focus on intravesical approaches). Immunotherapy Weekly. July 23, 2025; p 2975.